Regenerex Pharma (RGPX) EBIT Margin (2014 - 2020)
Regenerex Pharma (RGPX) reported EBIT Margin of 7874.03% for Q4 2020, down 711832.0% year-over-year from N/an in Q1 2020, and up 20.98% quarter-over-quarter from 9964.17% in Q3 2020.
Regenerex Pharma (RGPX) EBIT Margin (2014 - 2020) Analysis & Trends
Regenerex Pharma (RGPX) has 3 years of EBIT Margin data on file, last reported at 7874.03% in Q4 2020.
- EBIT Margin for Q4 2020 came in at 7874.03%, down 711832.0% year-over-year; the trailing twelve-month figure through Dec 2020 was 4406.31% (changed N/A YoY), and the FY2020 annual result was 2952.57%, changed N/A from the prior year.
- EBIT Margin grew to 7874.03% in Q4 2020 per RGPX's latest filing, from 9964.17% in the prior quarter.
- Over five years, EBIT Margin peaked at 755.72% in Q4 2019 and troughed at 13119.48% in Q2 2020.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -7,874.03% |
| Sep 30, 2020 | -9,964.17% |
| Jun 30, 2020 | -13,119.48% |
| Mar 31, 2020 | -2,308.64% |
| Dec 31, 2019 | -755.72% |
| Aug 31, 2014 | -22.79% |